Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.64 |
| ▸ | IGF2R | P11717 | 4/20 | 0.59 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.52 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.52 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.52 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GJA1 | P17302 | 1/20 | 0.45 |
| ▸ | GJB2 | P29033 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21845902 | 1.00 | CD209 (0.64) | CD209IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL12143166 | 1.00 | CD209 (0.64) | CD209IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL17993341 | 1.00 | CD209 (0.64) | CD209IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL19860864 | 1.00 | CD209 (0.64) | CD209IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL10174935 | 1.00 | CD209 (0.64) | CD209IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL17904701 | 1.00 | CD209 (0.64) | CD209IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL30891275 | 1.00 | CD209 (0.64) | CD209IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL29602137 | 1.00 | CD209 (0.64) | CD209IGF2RLGALS8LGALS3LGALS4 | |
| Hydrochloric Acid SCHEMBL30891424 | 0.99 | CD209 (0.62) | CD209IGF2RLGALS8LGALS3LGALS4 | |
| SCHEMBL16018775 | 0.96 | CD209 (0.60) | CD209IGF2RLGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615487-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024102633-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| US-9745355-B2 | Binding-site modified lectins and uses thereof | SMARTCELLS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745355-B2 | Binding-site modified lectins and uses thereof | SMARTCELLS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20140342980-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS INC (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140342980-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SIGLEC7, SIGLEC9, LGALS3BP | CD209 251/4885IGF2R 46/4885LGALS8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.